OECI projects

During the last General Assembly, the OECI Members approved the Board proposal to launch a European Cancer Mission Working Party to discuss on how the OECI Working Groups may participate to the incoming Horizon Europe Framework Programme, where a small number of “Missions” with specific goals will be launched establishing a comprehensive portfolio of projects.
The objectives of the Missions are to galvanise the EU Research and Innovation investment attracting funds from Member States and private investors, whilst taking into consideration the interests of the specific sectors and the sustainability of the actions: providing a direction for such investments is what a mission-oriented policy is about.
The Missions will be decided and co-designed as part of a strategic planning process, which will include a collaborative effort amongst Commission departments, Member States, the European Parliament and relevant stakeholders.
The OECI supports the launching of a cancer Mission and it is ready to collaborate with others in a Network of Networks where the main objectives must be presented. Therefore, a First Meeting of the interested actors that may be involved in our brainstorming is organised in Brussels on October 3rd at the OECI Headquarter.
The OECI considers mandatory fostering innovation on primary and secondary prevention as well, so as to reduce morbidity and give health systems more possibility to support the increasing costs of care.
Specific Pillars, already selected, may constitute the basic elements of the Working Party and Project for a Cancer Mission. They will be presented and discussed during the meeting in order to better define how to plan the project prosecution.
The already identified Pillars are below listed:
  • Incidence - Prevalence in aging
  • Primary Prevention
  • Basic research
  • Molecular pathology and precision medicine
  • Translational research
  • Outcomes cancer research - big data
  • Patient involvement
  • The OECI/ECCO vision
  • Quality and Organisation of a Cancer Centre
  • Health Economics
  • Training
Click the link to the 1st Meeting OECI European Mission Working Party.
The Joint Action on Rare Cancers is a multi-stakeholder collaboration coordinated by the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, involving 18 Member States and the European Commission. There are 35 partners participating to JARC, including 8 Ministries of Health/Cancer Control Programme representatives (Cyprus, Czech Republic, France, Ireland, Italy, Malta, Poland, and Spain), 27 universities, public health institutions, cancer registries, cancer institutes, patients’ associations and other cancer societies/organisations such as Organisation of European Cancer Institutes, the European Society for Paediatric Oncology - SIOPE).
The Joint Action on Rare Cancers aims to:
  • prioritise all rare cancers in the agenda of the EU and the Member States with regards to national cancer plans, harmonisation of practices and funding of research;
  • develop innovative and shared solutions so that European Reference Networks on Rare Cancers can improve the quality of care, the clinical practice guidelines and research, the medical & patient education and the epidemiological surveillance.
The OECI is an Associate partner to JARC coordinating the Work-Package 5 “Assuring Quality of Care” with the objectives to:
  • map the existing networks of care for all 11 families of adult rare cancers across all Member States and identify gaps in current scenario and inequalities of patient access to resources;
  • propose consistent and Europe-wide systems-based standards for all families of rare cancers and the networks serving them.
  • design Quality Assurance systems or processes specific to rare cancers supplemental to the ERN requirements (which would, in time, enable networks to become ERNs). The aim would be to promote and assure the standards and criteria in Objective 2 above will be maintained, a system of continuous quality improvement be established, best practice shared, and equality of care met for rare cancers across Europe.
The general objective of BenchCan was to benchmark comprehensive cancer care & yield best practice examples in a way that contributes to improving the quality of interdisciplinary patient treatment. To achieve this, the BenchCan project, ended on June 2016, addressed 6 specific objectives:
  • to collect, compare and align by consensus formation the standards, recommendations and accreditation criteria of comprehensive cancer care in selected European countries.
  • to review and refine a benchmarking tool that can be applied to comprehensive cancer care through interdisciplinary patient treatment.
  • to pilot the benchmark tool with particular attention to operations management and best clinical practice.
  • to maximise knowledge exchange and sharing of best practice between providers of comprehensive cancer care in member states and regions.
  • to ensure compatibility of the benchmarking tools with existing cancer care resources and services.
  • to ensure the sustainability and longer-term benefits of the project.
This project was developed using the best available evidence and the involvement of various stakeholders, such as cancer institutes, cancer patients' umbrella organisations, like the European Cancer Patient Coalition, and other relevant European agencies. As a result of the project, comprehensive benchmarking tools have been developed, as well as good practice examples of clinical practice (including patient experience) and operations management processes have been identified, collected, and presented in a database.
As part of the BenchCan project a Manual has been elaborated and may be downloaded at: http://www.oeci.eu/Benchcan/Doc/general/Resources/BenchCan_Manual_2016_FINAL.pdf.
It incorporates the developed benchmarking tools for cancer centres and cancer pathways and presents the necessary processes for carrying out an own benchmarking project by going through all the necessary detailed steps.